

Public Law 114–104
114th Congress

An Act

Dec. 18, 2015
[H.R. 2820]

To reauthorize the Stem Cell Therapeutic and Research Act of 2005, and for other purposes.

Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,

Stem Cell
Therapeutic and
Research
Reauthorization
Act of 2015.
42 USC 201 note.

SECTION 1. SHORT TITLE.

This Act may be cited as the “Stem Cell Therapeutic and Research Reauthorization Act of 2015”.

SEC. 2. REAUTHORIZATION OF THE C.W. BILL YOUNG CELL TRANSPLANTATION PROGRAM.

(a) IN GENERAL.—Section 379(d)(2)(B) of the Public Health Service Act (42 U.S.C. 274k(d)(2)(B)) is amended—

(1) by striking “remote collection” and inserting “collection”; and

(2) by inserting “including remote collection,” after “cord blood units,”.

(b) AUTHORIZATION OF APPROPRIATIONS.—Section 379B of the Public Health Service Act (42 U.S.C. 274m) is amended—

(1) by striking “\$30,000,000 for each of fiscal years 2011 through 2014 and”; and

(2) by inserting “and \$30,000,000 for each of fiscal years 2016 through 2020” before the period at the end.

Consultation.

(c) SECRETARY REVIEW ON STATE OF SCIENCE.—The Secretary of Health and Human Services, in consultation with the Director of the National Institutes of Health, the Commissioner of the Food and Drug Administration, and the Administrator of the Health Resources and Services Administration, including the Advisory Council on Blood Stem Cell Transplantation established under section 379(a) of the Public Health Service Act (42 U.S.C. 274k(a)), and other stakeholders, where appropriate given relevant expertise, shall conduct a review of the state of the science of using adult stem cells and birthing tissues to develop new types of therapies for patients, for the purpose of considering the potential inclusion of such new types of therapies in the C.W. Bill Young Cell Transplantation Program (established under such section 379) in addition to the continuation of ongoing activities. Not later than June 30, 2019, the Secretary shall submit to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives recommendations on the appropriateness of such new types of therapies for inclusion in the C.W. Bill Young Cell Transplantation Program.

Deadline.
Recommendations.